IL105519A0 - Labelled fibrinogen receptor antagonists,their preparation and their use - Google Patents
Labelled fibrinogen receptor antagonists,their preparation and their useInfo
- Publication number
- IL105519A0 IL105519A0 IL105519A IL10551993A IL105519A0 IL 105519 A0 IL105519 A0 IL 105519A0 IL 105519 A IL105519 A IL 105519A IL 10551993 A IL10551993 A IL 10551993A IL 105519 A0 IL105519 A0 IL 105519A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor antagonists
- fibrinogen
- fibrinogen receptor
- preparation
- labelled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/53—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4213930 | 1992-04-28 | ||
DE4214245A DE4214245A1 (de) | 1992-04-30 | 1992-04-30 | Tritiummarkierte fibrinogen-rezeptor-antagonisten, deren verwendung und verfahren zu ihrer herstellung |
Publications (1)
Publication Number | Publication Date |
---|---|
IL105519A0 true IL105519A0 (en) | 1993-08-18 |
Family
ID=25914315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL105519A IL105519A0 (en) | 1992-04-28 | 1993-04-27 | Labelled fibrinogen receptor antagonists,their preparation and their use |
Country Status (16)
Country | Link |
---|---|
US (1) | US5677466A (no) |
EP (1) | EP0567967B1 (no) |
JP (1) | JPH0650977A (no) |
KR (1) | KR940005271A (no) |
AT (1) | ATE140225T1 (no) |
AU (1) | AU670778B2 (no) |
CA (1) | CA2094963A1 (no) |
DE (1) | DE59303178D1 (no) |
DK (1) | DK0567967T3 (no) |
ES (1) | ES2092170T3 (no) |
FI (1) | FI931881A (no) |
GR (1) | GR3020740T3 (no) |
IL (1) | IL105519A0 (no) |
MX (1) | MX9302446A (no) |
NO (1) | NO180046C (no) |
NZ (1) | NZ247511A (no) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4304650A1 (de) * | 1993-02-16 | 1994-08-18 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
DE4324580A1 (de) * | 1993-07-22 | 1995-01-26 | Thomae Gmbh Dr K | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US5925635A (en) * | 1996-04-17 | 1999-07-20 | Dupont Pharmaceuticals Company | N-(amidinophenyl) cyclourea analogs as factor XA inhibitors |
WO1999026919A1 (fr) * | 1997-11-20 | 1999-06-03 | Teijin Limited | Derives de biphenylamidine |
DK1043310T3 (da) * | 1997-11-20 | 2004-10-25 | Teijin Ltd | Biphenylamidinderivater |
ATE339204T1 (de) * | 1999-01-28 | 2006-10-15 | Teijin Ltd | Freisetzungsregulierende zubereitungen |
WO2004024707A2 (en) * | 2002-09-16 | 2004-03-25 | Abbott Laboratories | Process for preparing amine type substituted benzofurans |
US6822101B2 (en) | 2002-09-16 | 2004-11-23 | Abbott Laboratories | Process for preparing amine-substituted benzofurans |
EP3489692A1 (de) * | 2017-11-28 | 2019-05-29 | Siemens Healthcare Diagnostics Products GmbH | Prothrombinzeit-reagenz enthaltend einen eisenchelator |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5039805A (en) * | 1988-12-08 | 1991-08-13 | Hoffmann-La Roche Inc. | Novel benzoic and phenylacetic acid derivatives |
US5084466A (en) * | 1989-01-31 | 1992-01-28 | Hoffmann-La Roche Inc. | Novel carboxamide pyridine compounds which have useful pharmaceutical utility |
DE4134467A1 (de) * | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE4035961A1 (de) * | 1990-11-02 | 1992-05-07 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE4102024A1 (de) * | 1991-01-24 | 1992-07-30 | Thomae Gmbh Dr K | Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE4107857A1 (de) * | 1991-03-12 | 1992-09-17 | Thomae Gmbh Dr K | Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE4124942A1 (de) * | 1991-07-27 | 1993-01-28 | Thomae Gmbh Dr K | 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE4127404A1 (de) * | 1991-08-19 | 1993-02-25 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
-
1993
- 1993-04-26 ES ES93106725T patent/ES2092170T3/es not_active Expired - Lifetime
- 1993-04-26 KR KR1019930006959A patent/KR940005271A/ko not_active Application Discontinuation
- 1993-04-26 EP EP93106725A patent/EP0567967B1/de not_active Expired - Lifetime
- 1993-04-26 DK DK93106725.0T patent/DK0567967T3/da active
- 1993-04-26 AT AT93106725T patent/ATE140225T1/de not_active IP Right Cessation
- 1993-04-26 DE DE59303178T patent/DE59303178D1/de not_active Expired - Fee Related
- 1993-04-27 NZ NZ247511A patent/NZ247511A/en unknown
- 1993-04-27 FI FI931881A patent/FI931881A/fi not_active Application Discontinuation
- 1993-04-27 CA CA002094963A patent/CA2094963A1/en not_active Abandoned
- 1993-04-27 JP JP5100789A patent/JPH0650977A/ja active Pending
- 1993-04-27 MX MX9302446A patent/MX9302446A/es not_active IP Right Cessation
- 1993-04-27 IL IL105519A patent/IL105519A0/xx unknown
- 1993-04-27 NO NO931528A patent/NO180046C/no unknown
- 1993-04-27 AU AU37153/93A patent/AU670778B2/en not_active Ceased
-
1995
- 1995-05-23 US US08/447,667 patent/US5677466A/en not_active Expired - Fee Related
-
1996
- 1996-08-07 GR GR960402105T patent/GR3020740T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2094963A1 (en) | 1993-10-29 |
KR940005271A (ko) | 1994-03-21 |
AU3715393A (en) | 1993-11-04 |
AU670778B2 (en) | 1996-08-01 |
ATE140225T1 (de) | 1996-07-15 |
DE59303178D1 (de) | 1996-08-14 |
EP0567967B1 (de) | 1996-07-10 |
MX9302446A (es) | 1994-03-31 |
NZ247511A (en) | 1995-02-24 |
DK0567967T3 (da) | 1996-11-18 |
NO931528D0 (no) | 1993-04-27 |
GR3020740T3 (en) | 1996-11-30 |
NO931528L (no) | 1993-10-29 |
JPH0650977A (ja) | 1994-02-25 |
US5677466A (en) | 1997-10-14 |
FI931881A0 (fi) | 1993-04-27 |
ES2092170T3 (es) | 1996-11-16 |
NO180046B (no) | 1996-10-28 |
EP0567967A1 (de) | 1993-11-03 |
NO180046C (no) | 1997-02-05 |
FI931881A (fi) | 1993-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Feltkamp | Conjugation of Fluorescein Isothiocyanate to Antibodies I. EXPERIMENT ON THE CONDITIONS OF CONJUGATION. | |
Kurlander et al. | The binding of human immunoglobulin G1 monomer and small, covalently cross-linked polymers of immunoglobulin G1 to human peripheral blood monocytes and polymorphonuclear leukocytes | |
Sandberg et al. | Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ | |
Tuddenham et al. | The properties of factor VIII coagulant activity prepared by immunoadsorbent chromatography | |
Koide | Isolation and characterization of antithrombin III from human, porcine and rabbit plasma, and rat serum | |
Qian et al. | Isolation and characterization of sheep lactoferrin, an inhibitor of platelet aggregation and comparison with human lactoferrin | |
IL105519A0 (en) | Labelled fibrinogen receptor antagonists,their preparation and their use | |
ATE68826T1 (de) | Verfahren zur herstellung von reifem, menschlichem serum-albumin. | |
Bing et al. | Purification of Subcomponents Clq, Cl [rbar] and Cl [sbar] of the First Component of Complement from Cohn Fraction I by Affinity Chromatography | |
Pihko et al. | Rabbit α-fetoprotein: Immunochemical purification and partial characterization | |
Arlaud et al. | A study on the structure and interactions of the C1 sub-components C1r and C1s in the fluid phase | |
Kelm et al. | Human platelet osteonectin: release, surface expression, and partial characterization | |
de Romeuf et al. | Heparin binding assay of von Willebrand factor (vWF) in plasma milieu–evidence of the importance of the multimerization degree of vWF | |
Moake et al. | Interaction of platelets, von Willebrand factor and ristocetin during platelet agglutination | |
Kemball-Cook et al. | Factor VIII procoagulant protein interacts with phospholipid vesicles via its 80 kDa light chain | |
Dhawan et al. | A novel peptide from amyloid P component supports cell attachment | |
Muntz et al. | Properties of post-infusion factor VIII in von Willebrand's disease | |
Mascelli et al. | Characterization of a fragment of bovine von Willebrand factor that binds to platelets | |
DE69434118D1 (de) | Klonierung und rekombinante herstellung des crf-rezeptors (crf=corticotropin ausloese faktor) | |
Jenkins et al. | Antibodies against Platelet Membrane Glycoproteins II. INFLUENCE ON ADP‐AND COLLAGEN‐INDUCED PLATELET AGGREGATION, CROSSED IMMUNOELECTROPHORESIS STUDIES AND RELEVANCE TO GLANZMANN'S THROMBASTHENIA | |
CA2180957A1 (en) | Cloning and recombinant production of crf receptor(s) | |
Suzuki et al. | The influence of 2-mercaptoethanol on von Willebrand factor and bovine platelet aggregating factor | |
Cornelius et al. | Adsorption of immunoglobulin G and anti-factor VIII inhibitory antibody from haemophiliac plasma to derivatized polystyrenes | |
Lane et al. | Affinity chromatography of human factor VIII using human and rabbit antibodies to factor VIII | |
Ternisien et al. | Effect of phosphopyridoxylation on thrombin interaction with platelet glycoprotein Ib |